Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Ovarian Cancer, Endometrial Cancer, Cervical Cancer
About this trial
This is an interventional treatment trial for Ovarian Cancer focused on measuring PTK787, Metastatic breast cancer, Refractory gynecological cancer
Eligibility Criteria
Inclusion Criteria: Recurrent gynecological cancers or metastatic breast cancer. Initial diagnosis must be confirmed histologically. Measurable disease or nonmeasurable disease Age > 18 years ECOG performance 0,1,2 4 weeks or greater since major surgery, 3 weeks or greater since chemotherapy Certain lab values Negative for proteinuria Exclusion Criteria: Four or more treatment regimens History or presence of uncontrolled CNS disease Prior biologic or immunotherapies less than 3 weeks prior to registration Prior full field radiotherapy less than 4 weeks or limited field radiotherapy less than 2 weeks prior to registration Prior therapy with anti-VEGF agents Peripheral neuropathy with functional impairment > CTC grade 2 Pregnant or breast feeding Concurrent severe and/or uncontrolled medical condition Chronic renal disease Acute or chronic liver disease Impairment of gastrointestinal function or GI disease Confirmed diagnosis of HIV infection are excluded at the investigators discretion Therapeutic warfarin sodium or similar oral anticoagulants that are metabolized by the cytochrome p450 system.
Sites / Locations
- Massachusetts General Hospital
- Dana-Farber Cancer Institute
Arms of the Study
Arm 1
Experimental
Docetaxel / PTK787
Docetaxel: Lead In: Given intravenously on Day 1 and Day 14 Afer Lead in: Given intravenously on day 1, 8, 15, 22 of each 28-day cycle. PTK787: Lead In: Given orally on day 4 and day 14 After Lead In: Given orally once a day.